A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT01999335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects
Study identification
- NCT ID
- NCT01999335
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Interventions
- Dexamethasone Drug
- Oprozomib Drug
- Pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 29, 2014
- Primary completion
- Apr 24, 2019
- Completion
- Apr 24, 2019
- Last update posted
- Apr 26, 2021
2014 – 2019
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Associates For Research and Exellence, cCare | Encinitas | California | — | — |
| James R. Berenson, MD, Inc. | West Hollywood | California | — | — |
| Innovative Clinical Research Institute | Whittier | California | — | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | — | — |
| Oncology Hematology West PC, dba Nebraska Cancer Specialists | Omaha | Nebraska | — | — |
| Weill Cornell Medical College-New York Presbyterian Hospital | New York | New York | — | — |
| Levine Cancer Institute | Charlotte | North Carolina | — | — |
| Duke University Medical Center | Durham | North Carolina | — | — |
| Willamette Valley Cancer Institute and Research Center | Springfield | Oregon | — | — |
| Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | — | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Tennessee Oncology, PLLC / Sarah Cannon Research Institute | Nashville | Tennessee | — | — |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | — | — |
| Cancer Care Centers of South Texas-HOAST | San Antonio | Texas | — | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | — | — |
| Virginia Oncology Associates | Norfolk | Virginia | — | — |
| Yakima Valley Memorial Hospital/North Star Lodge | Yakima | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01999335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2021 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01999335 live on ClinicalTrials.gov.